Biotech Values

[turtlepower]

Actually there could be a slight difference in the patient population for the two drugs. The abiraterone population included patients treated twice with chemo which means there probably were patients already treated with docetaxel and then mitoxantrone. In the cabazitaxel study patients who had previously received mitoxantrone were excluded so i imagine the patient population was strictly 1st line and less sick than the patients in the abiraterone study.